Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Return on Invested Capital (2016 - 2025)

Historic Return on Invested Capital for ImmunityBio (IBRX) over the last 11 years, with Q3 2025 value amounting to 0.48%.

  • ImmunityBio's Return on Invested Capital fell 7800.0% to 0.48% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.48%, marking a year-over-year decrease of 7800.0%. This contributed to the annual value of 25.91% for FY2023, which is 232300.0% up from last year.
  • Latest data reveals that ImmunityBio reported Return on Invested Capital of 0.48% as of Q3 2025, which was down 7800.0% from 1.17% recorded in Q2 2025.
  • ImmunityBio's Return on Invested Capital's 5-year high stood at 1.74% during Q3 2021, with a 5-year trough of 2.18% in Q1 2025.
  • For the 5-year period, ImmunityBio's Return on Invested Capital averaged around 0.99%, with its median value being 1.17% (2022).
  • In the last 5 years, ImmunityBio's Return on Invested Capital crashed by -722900bps in 2021 and then surged by 6600bps in 2025.
  • ImmunityBio's Return on Invested Capital (Quarter) stood at 1.55% in 2021, then increased by 1bps to 1.57% in 2022, then increased by 10bps to 1.72% in 2023, then dropped by -27bps to 1.25% in 2024, then crashed by -62bps to 0.48% in 2025.
  • Its Return on Invested Capital stands at 0.48% for Q3 2025, versus 1.17% for Q2 2025 and 2.18% for Q1 2025.